Effect of ABCC2 (MRP2) Transport Function on Erythromycin Metabolism

The macrolide antiobiotic erythromycin undergoes extensive hepatic metabolism and is commonly used as a probe for cytochrome P450 (CYP) 3A4 activity. By means of a transporter screen, erythromycin was identified as a substrate for the transporter ABCC2 (MRP2) and its murine ortholog, Abcc2. Because these proteins are highly expressed on the biliary surface of hepatocytes, we hypothesized that impaired Abcc2 function may influence the rate of hepatobiliary excretion and thereby enhance erythromycin metabolism. Using Abcc2 knockout mice, we found that Abcc2 deficiency was associated with a significant increase in erythromycin metabolism, whereas murine Cyp3a protein expression and microsomal Cyp3a activity were not affected. Next, in a cohort of 108 human subjects, we observed that homozygosity for a common reduced‐function variant in ABCC2 (rs717620) was also linked to an increase in erythromycin metabolism but was not correlated with the clearance of midazolam. These results suggest that impaired ABCC2 function can alter erythromycin metabolism, independent of changes in CYP3A4 activity.

[1]  P. Tulkens,et al.  Antibiotic efflux pumps in eukaryotic cells: occurrence and impact on antibiotic cellular pharmacokinetics, pharmacodynamics and toxicodynamics. , 2003, The Journal of antimicrobial chemotherapy.

[2]  J. Verweij,et al.  Population Pharmacokinetic Model for Docetaxel in Patients with Varying Degrees of Liver Function: Incorporating Cytochrome P450 3A Activity Measurements , 2008, Clinical pharmacology and therapeutics.

[3]  P. Dawson,et al.  Interaction of Macrolide Antibiotics with Intestinally Expressed Human and Rat Organic Anion-Transporting Polypeptides , 2009, Drug Metabolism and Disposition.

[4]  S. Clarke,et al.  Transcriptional Repression of Hepatic Cytochrome P450 3A4 Gene in the Presence of Cancer , 2006, Clinical Cancer Research.

[5]  Christopher J. Endres,et al.  Interplay of drug metabolism and transport: a real phenomenon or an artifact of the site of measurement? , 2009, Molecular pharmaceutics.

[6]  G. Wilkinson,et al.  The erythromycin breath test reflects P‐glycoprotein function independently of cytochrome P450 3A activity , 2006, Clinical pharmacology and therapeutics.

[7]  J. Verweij,et al.  Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients , 2004, Clinical Cancer Research.

[8]  J. Verweij,et al.  Irinotecan‐induced Diarrhea: Functional Significance of the Polymorphic ABCC2 Transporter Protein , 2007, Clinical pharmacology and therapeutics.

[9]  R. Evers,et al.  Role of the N-terminal Transmembrane Region of the Multidrug Resistance Protein MRP2 in Routing to the Apical Membrane in MDCKII Cells* , 2002, The Journal of Biological Chemistry.

[10]  E. Schuetz,et al.  Mdr1 limits CYP3A metabolism in vivo. , 2000, Molecular pharmacology.

[11]  J. Goldstein,et al.  Midazolam Metabolism in Cytochrome P450 3A Knockout Mice Can Be Attributed to Up-Regulated CYP2C Enzymes , 2008, Molecular Pharmacology.

[12]  L. Benet,et al.  Effects of Uptake and Efflux Transporter Inhibition on Erythromycin Breath Test Results , 2007, Clinical pharmacology and therapeutics.

[13]  E. Shin,et al.  Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan‐pharmacokinetics and clinical outcome in patients with advanced non‐small cell lung cancer , 2007, Cancer.

[14]  P. Beale,et al.  Optimizing the erythromycin breath test for use in cancer patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  Soma Das,et al.  Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Watkins,et al.  Cytochrome P450 3A4 and P‐glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin , 2002, Clinical pharmacology and therapeutics.

[17]  E. Schuetz,et al.  Human MDR1 and mouse mdr1a P-glycoprotein alter the cellular retention and disposition of erythromycin, but not of retinoic acid or benzo(a)pyrene. , 1998, Archives of biochemistry and biophysics.

[18]  D. Keppler,et al.  Export pumps for anionic conjugates encoded by MRP genes. , 1999, Advances in enzyme regulation.

[19]  L. Benet,et al.  IN VITRO AND IN VIVO CORRELATION OF HEPATIC TRANSPORTER EFFECTS ON ERYTHROMYCIN METABOLISM: CHARACTERIZING THE IMPORTANCE OF TRANSPORTER-ENZYME INTERPLAY , 2006, Drug Metabolism and Disposition.

[20]  J. Verweij,et al.  Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes. , 2004, Journal of the National Cancer Institute.

[21]  H. Endou,et al.  Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. , 2002, Molecular pharmacology.

[22]  Ji-Youn Han,et al.  Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. , 2009, Lung cancer.

[23]  D. Keppler,et al.  Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. , 1999, Biochimica et biophysica acta.

[24]  Y Vanrenterghem,et al.  Measurement of hepatic and intestinal CYP3A4 and PGP activity by combined po + iv [14C]erythromycin breath and urine test. , 2003, American journal of physiology. Gastrointestinal and liver physiology.

[25]  A. Sparreboom,et al.  Influence of Solute Carriers on the Pharmacokinetics of CYP3A4 Probes , 2008, Clinical pharmacology and therapeutics.

[26]  T. Eschenhagen,et al.  High‐dose methotrexate in pediatric acute lymphoblastic leukemia: Impact of ABCC2 polymorphisms on plasma concentrations , 2006, Clinical pharmacology and therapeutics.

[27]  P. Watkins,et al.  P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients , 1994, Clinical pharmacology and therapeutics.

[28]  G. Mishra,et al.  Enhanced Corneal Absorption of Erythromycin by Modulating P-Glycoprotein and MRP Mediated Efflux with Corticosteroids , 2009, Pharmaceutical Research.

[29]  I. Cascorbi,et al.  Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function , 2011, The Pharmacogenomics Journal.

[30]  J B Houston,et al.  Microsomal prediction of in vivo clearance and associated interindividual variability of six benzodiazepines in humans , 2005, Xenobiotica; the fate of foreign compounds in biological systems.

[31]  P. Watkins.  Erythromycin breath test and clinical transplantation. , 1996, Therapeutic drug monitoring.

[32]  H. Kroemer,et al.  Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex , 2007, The Pharmacogenomics Journal.

[33]  M. Relling,et al.  O-demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. , 1994, Molecular pharmacology.

[34]  D. Wagner,et al.  CYP3A4 and the erythromycin breath test , 1998, Clinical pharmacology and therapeutics.

[35]  E. van de Steeg,et al.  Species-Dependent Transport and Modulation Properties of Human and Mouse Multidrug Resistance Protein 2 (MRP2/Mrp2, ABCC2/Abcc2) , 2008, Drug Metabolism and Disposition.

[36]  A. Wolff,et al.  Pharmacogenetic Pathway Analysis of Docetaxel Elimination , 2009, Clinical pharmacology and therapeutics.

[37]  R. Franke,et al.  Pharmacogenetics of drug transporters. , 2010, Current pharmaceutical design.

[38]  Mark M. Roden,et al.  Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein , 1999, Pharmaceutical Research.

[39]  M. Carducci,et al.  Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  S. Bates,et al.  Effect of Common CYP3A4 and CYP3A5 Variants on the Pharmacokinetics of the Cytochrome P450 3A Phenotyping Probe Midazolam in Cancer Patients , 2005, Clinical Cancer Research.

[41]  M. Narabayashi,et al.  Association of ATP-binding cassette, sub-family C, number 2 (ABCC2) genotype with pharmacokinetics of irinotecan in Japanese patients with metastatic colorectal cancer treated with irinotecan plus infusional 5-fluorouracil/leucovorin (FOLFIRI). , 2008, Biological & pharmaceutical bulletin.

[42]  P. Watkins,et al.  Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. , 1989, The Journal of clinical investigation.

[43]  Toshinori Yamamoto,et al.  POSSIBLE INVOLVEMENT OF ORGANIC ANION TRANSPORTER 2 ON THE INTERACTION OF THEOPHYLLINE WITH ERYTHROMYCIN IN THE HUMAN LIVER , 2005, Drug Metabolism and Disposition.